SCHEMBL4325934

SCHEMBL4325934

O=C1Nc2ccccc2SC1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.53
KDM4E B2RXH2 3/20 0.53
TDP1 Q9NUW8 3/20 0.53
POLB P06746 2/20 0.53
ALOX15 P16050 2/20 0.53
GLA P06280 1/20 0.53
USP2 O75604 1/20 0.53
ESR1 P03372 1/20 0.53
THRB P10828 1/20 0.53
HPGD P15428 1/20 0.53
PTPN7 P35236 1/20 0.53
RECQL P46063 1/20 0.53
ESR2 Q92731 1/20 0.53
CTDSP1 Q9GZU7 1/20 0.53
MAPT P10636 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HTT P42858 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31542005 1.00 HSD17B10 (0.53) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL10352528 0.81 HSD17B10 (0.50) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL28768922 0.77 HSD17B10 (0.53) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL11034753 0.77 HSD17B10 (0.61) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL9024189 0.77 HSD17B10 (0.53) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL24125191 0.77 CREBBP (0.57) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL2745305 0.77 CREBBP (0.57) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL10729385 0.77 HSD17B10 (0.65) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL3626456 0.74 CA2 (0.62) HSD17B10KDM4ETDP1POLBALOX15
SCHEMBL4969852 0.74 MAPT (0.51) HSD17B10KDM4ETDP1POLBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579363-B2 Bicyclic compounds and compositions as PDF inhibitors IRM LLC (BM) 2009-08-25 US disclosed
EP-1651643-A4 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS IRM LLC (BM) 2008-10-08 EP disclosed
US-20070259852-A1 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS IRM LLC 2007-11-08 US disclosed
US-7253164-B2 Bicyclic compounds and compositions as PDF inhibitors IRM LLC (BM) 2007-08-07 US disclosed
EP-1651643-A2 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS IRM, LLC (BM) 2006-05-03 EP disclosed
US-20050197326-A1 Bicyclic compounds and compostions as PDF inhibitors IRM LLC 2005-09-08 US disclosed
WO-2005011611-A2 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS IRM, LLC (BM) 2005-02-10 WO disclosed
CN-1033584-C Benzo-fused lactams that promote release of growth hormone MERCK & CO INC (US) 1996-12-18 CN disclosed
EP-0513974-B1 Novel benzo-fused lactams that promote the release of growth hormone MERCK & CO INC (US) 1996-09-04 EP disclosed
EP-0441539-B1 Thiazine (or oxazine) derivatives and preparation thereof TANABE SEIYAKU CO (JP) 1996-04-10 EP disclosed
US-5281592-A Calcium antagonist, antiischemic agents, brains, nervous system disorders TANABE SEIYAKU CO., LTD. (JP) 1994-01-25 US disclosed
US-5246929-A Prophylaxis or treatment of ischemic encephalopathia TANABE SEIYAKU CO., LTD. (JP) 1993-09-21 US disclosed
US-5206235-A Animal growth regulators; stimulants MERCK & CO., INC. (US) 1993-04-27 US disclosed
EP-0513974-A1 Novel benzo-fused lactams that promote the release of growth hormone MERCK & CO. INC. (US) 1992-11-19 EP disclosed
WO-1992016524-A1 BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE MERCK & CO., INC. (US) 1992-10-01 WO disclosed
EP-0488008-A1 Heterocyclic substituted piperazinoalkylbenzoxazine and -thiazine compounds, process for their preparation and therapeutic drugs containing them Kali-Chemie Pharma GmbH (DE) 1992-06-03 EP disclosed
EP-0488009-A2 Piperidinoalkyl-benzoxazine-and-thiazine-compounds, processes for their preparation and drugs containing them Kali-Chemie Pharma GmbH (DE) 1992-06-03 EP disclosed
EP-0441539-A2 Thiazine (or oxazine) derivatives and preparation thereof TANABE SEIYAKU CO., LTD. (JP) 1991-08-14 EP disclosed
US-4584300-A Platelet anti-aggregative- and calcium antagonistic -1,4-benzothiazin-3-one derivatives, compositions, and methods of use therefor SANTEN PHARMACEUTICAL CO., LTD. (JP) 1986-04-22 US disclosed
EP-0116368-A1 Benzothiazine derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 1984-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197326-A1 Bicyclic compounds and compostions as PDF inhibitors PDF, FDPS, DCTPP1 HSD17B10 2730/4885KDM4E 1224/4885TDP1 124/4885
US-20070259852-A1 BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS PDF, FDPS, DCTPP1 HSD17B10 1950/4885KDM4E 1204/4885TDP1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.